Literature DB >> 11159969

Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice.

W T Jansen1, S Hogenboom, M J Thijssen, J P Kamerling, J F Vliegenthart, J Verhoef, H Snippe, A F Verheul.   

Abstract

The immunogenicity and protective capacity of Streptococcus pneumoniae 6B capsular polysaccharide (PS)-derived synthetic phosphate-containing disaccharide (Rha-ribitol-P-), trisaccharide (ribitol-P-Gal-Glc-), and tetrasaccharide (Rha-ribitol-P-Gal-Glc-)-protein conjugates in rabbits and mice were studied. In rabbits, all saccharides conjugated to keyhole limpet hemocyanin (KLH) evoked high levels of pneumococcal (Pn) type 6B antibodies that facilitated type-specific phagocytosis. Unlike the disaccharide rabbit antisera, tri- and tetrasaccharide rabbit antisera also reacted with 6A PS in an enzyme-linked immunosorbent assay (ELISA) and promoted phagocytosis of 6A pneumococci. All these rabbit antisera passively protected mice against a Pn 6B challenge. The disaccharide conjugate-induced antiserum, however, failed to protect mice against a 6A challenge. In mice, phagocytic and protective anti-Pn 6B antibodies were only induced by the tetrasaccharide conjugate and not by PS 6B or PS 6B-protein conjugates. These antibodies did not cross-react with 6A PS in ELISA and were unable to phagocytize 6A pneumococci. In conclusion, the disaccharide and tetrasaccharide conjugates already contain epitopes capable of inducing 6B-specific, fully protective antibodies in rabbits and mice, respectively.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159969      PMCID: PMC97953          DOI: 10.1128/IAI.69.2.787-793.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Fcgamma receptor polymorphisms determine the magnitude of in vitro phagocytosis of Streptococcus pneumoniae mediated by pneumococcal conjugate sera.

Authors:  W T Jansen; M A Breukels; H Snippe; L A Sanders; A F Verheul; G T Rijkers
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

2.  Towards a synthetic pneumococcal vaccine: synthetic oligosaccharides as tools for improving the specificity of enzyme-linked immunosorbent assays.

Authors:  H Snippe; W T Jansen; J P Kamerling; D J Lefeber
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

3.  The influence of the adjuvant Quil A on the epitope specificity of meningococcal lipopolysaccharide anti-carbohydrate antibodies.

Authors:  A F Verheul; J T Poolman; H Snippe; J Verhoef
Journal:  Mol Immunol       Date:  1991-11       Impact factor: 4.407

4.  Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants.

Authors:  J M Borgoño; A A McLean; P P Vella; A F Woodhour; I Canepa; W L Davidson; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1978-01

5.  Immunochemical studies of conjugates of isomaltosyl oligosaccharides to lipid: specificities and reactivities of the antibodies formed in rabbits to stearyl-isomaltosyl oligosaccharides.

Authors:  C Wood; E A Kabat
Journal:  Arch Biochem Biophys       Date:  1981-11       Impact factor: 4.013

6.  Synthetic trimer and tetramer of 3-beta-D-ribose-(1-1)-D-ribitol-5-phosphate conjugated to protein induce antibody responses to Haemophilus influenzae type b capsular polysaccharide in mice and monkeys.

Authors:  C C Peeters; D Evenberg; P Hoogerhout; H Käyhty; L Saarinen; C A van Boeckel; G A van der Marel; J H van Boom; J T Poolman
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

7.  Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children.

Authors:  M Leinonen; A Säkkinen; R Kalliokoski; J Luotonen; M Timonen; P H Mäkelä
Journal:  Pediatr Infect Dis       Date:  1986 Jan-Feb

8.  Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates.

Authors:  A F Verheul; A A Versteeg; M J De Reuver; M Jansze; H Snippe
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

9.  Serotypes of Streptococcus pneumoniae causing disease.

Authors:  B M Gray; G M Converse; H C Dillon
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

10.  Characterization of the murine immune response to type 6 pneumococcal polysaccharide.

Authors:  R L Fairchild; H Braley-Mullen
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

View more
  16 in total

1.  Total synthesis of an antigenic heptasaccharide motif found in the cell-wall lipooligosaccharide of Mycobacterium gordonae strain 989.

Authors:  Chinmoy Mukherjee; Anup Kumar Misra
Journal:  Glycoconj J       Date:  2008-02-19       Impact factor: 2.916

2.  Concise synthesis of a heptasaccharide antigen found in the cell-wall lipopolysaccharide of Mycobacterium gordonae strain 990.

Authors:  Rajib Panchadhayee; Anup Kumar Misra
Journal:  Glycoconj J       Date:  2008-06-21       Impact factor: 2.916

3.  Concise synthesis of the pentasaccharide O-antigen of Escherichia coli O83:K24:H31 present in the Colinfant vaccine.

Authors:  Pintu Kumar Mandal; Anup Kumar Misra
Journal:  Glycoconj J       Date:  2008-04-15       Impact factor: 2.916

4.  A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection.

Authors:  Sharavathi Guddehalli Parameswarappa; Katrin Reppe; Andreas Geissner; Petra Ménová; Subramanian Govindan; Adam D J Calow; Annette Wahlbrink; Markus W Weishaupt; Bopanna Ponnappa Monnanda; Roland Lawrence Bell; Liise-Anne Pirofski; Norbert Suttorp; Leif Erik Sander; Martin Witzenrath; Claney Lebev Pereira; Chakkumkal Anish; Peter H Seeberger
Journal:  Cell Chem Biol       Date:  2016-11-03       Impact factor: 8.116

Review 5.  Carbohydrate vaccines: developing sweet solutions to sticky situations?

Authors:  Rena D Astronomo; Dennis R Burton
Journal:  Nat Rev Drug Discov       Date:  2010-04       Impact factor: 84.694

6.  A structurally diversified linker enhances the immune response to a small carbohydrate hapten.

Authors:  Tomasz Lipinski; Thanh Luu; Pavel I Kitov; Adam Szpacenko; David R Bundle
Journal:  Glycoconj J       Date:  2011-05-05       Impact factor: 2.916

7.  Identification of a simple chemical structure associated with protective human antibodies against multiple pneumococcal serogroups.

Authors:  Saeyoung Park; Archana R Parameswar; Alexei V Demchenko; Moon H Nahm
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

8.  Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3.

Authors:  Dirk J Lefeber; Barry Benaissa-Trouw; Johannes F G Vliegenthart; Johannis P Kamerling; Wouter T M Jansen; Kees Kraaijeveld; Harm Snippe
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

9.  Synthesis, conjugation, and immunological evaluation of the serogroup 6 pneumococcal oligosaccharides.

Authors:  Archana R Parameswar; In Ho Park; Rina Saksena; Pavol Kovác; Moon H Nahm; Alexei V Demchenko
Journal:  Chembiochem       Date:  2009-12-14       Impact factor: 3.164

10.  Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197.

Authors:  Fatme Mawas; Jutta Niggemann; Christopher Jones; Michael J Corbel; Johannis P Kamerling; Johannes F G Vliegenthart
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.